FDA approves first generic pergolide tablet for horses with PPID

The equine PPID market has a new FDA-approved entrant: Zygolide, a pergolide tablet from Dechra that became the first generic approved for control of clinical signs associated with pituitary pars intermedia dysfunction, also called equine Cushing’s disease, in horses. FDA lists the approval date as December 19, 2025, with the public announcement following on January 9, 2026. The approval gives veterinarians an alternative to the long-established brand Prascend in a disease area where treatment is often lifelong. (fda.gov)

That matters because PPID is a familiar, growing management issue in aging horses. Dechra, citing UC Davis background information, said the condition affects about 21% of horses 15 years and older, with prevalence rising further in horses over 30. In practice, pergolide has been the standard medical therapy for years, and FDA notes that Prascend was first approved in 2011. Until now, however, veterinarians had only one FDA-approved pergolide brand for horses in the U.S. market. (dechra-us.com)

The regulatory details are straightforward. In its FOI summary, FDA said Zygolide was approved under ANADA 200-823 as a generic version of Prascend and found to be bioequivalent based on an in vivo blood-level study in 24 healthy, fasted horses. The labeled starting dose is 2 mcg/kg orally once daily, with adjustment to effect up to 4 mcg/kg daily. The product is supplied as 1 mg tablets in 60-count and 160-count cartons, and it is prescription-only. (animaldrugsatfda.fda.gov)

Dechra is positioning the product around administration and affordability as much as around equivalence. In its January 5 announcement, the company said Zygolide is peppermint-flavored, uses 360-degree scoring on all sides to make splitting easier, and is intended to offer cost relief for horses that need higher pergolide doses. That messaging also shows up in promotional placements published by The Horse, which pair the administration-focused features with owner-facing quality-of-life language such as “Rediscover the partnership with Zygolide” and “Help your horse feel their best so you can enjoy more happy moments together.” (dechra-us.com)

Company commentary has focused on access and day-to-day usability. Dechra’s equine medical affairs lead, Dr. Greg Schmid, said the approval brings “a high-quality, cost-effective option” to market and highlighted the tablet’s scoring and flavor profile as features that may reduce administration stress. While independent expert reaction specific to Zygolide appears limited so far, the broader clinical context is clear: PPID cases often require long-term dose adjustments and regular reassessment, so formulation and handling details can matter in real-world adherence. The owner-directed ad language in The Horse reinforces that Dechra is not just selling equivalence, but also the promise of preserving comfort, routine, and the horse-owner bond during chronic care. (dechra-us.com)

Why it matters: For veterinary professionals, this is less about a new mechanism than about a new operating reality. A generic pergolide could widen access for pet parents managing senior horses on chronic therapy, particularly in cases where cost has delayed treatment initiation or made dose escalation harder to sustain. It may also give veterinarians a more flexible conversation around compliance if tablet palatability and splitting are improved in practice. At the same time, clinicians will still need to set expectations around monitoring and safety: FDA and Dechra both note that pergolide tablets should not be crushed, and Dechra says treatment may cause loss of appetite, weight loss, low energy, or behavioral changes. The marketing language now circulating to horse owners suggests Dechra sees emotional and lifestyle benefits as part of the adherence story, which may resonate in conversations about long-term management. (fda.gov)

There’s also a market signal here. FDA’s recent approvals page shows Zygolide joining a broader flow of equine drug activity, but its significance is distinct because it introduces generic competition into a well-established endocrine category rather than opening a new therapeutic class. If pricing remains meaningfully lower through equine pharmacies, the product could reshape how some practices approach long-term PPID management, especially for horses needing higher or adjusted dosing over time. That inference is based on Dechra’s explicit cost-relief positioning and the chronic nature of PPID care. The parallel owner-facing campaign in The Horse suggests the launch strategy is aimed not only at veterinarians and pharmacies, but also at owners making daily treatment decisions at home. (fda.gov)

What to watch: The next questions are commercial and clinical: how widely Zygolide is stocked by distributors and online pharmacies, whether veterinarians see measurable gains in adherence or acceptance, and whether Dechra publishes more post-launch data on pricing, uptake, or administration outcomes in the months ahead. It will also be worth watching whether the product’s quality-of-life messaging translates into stronger owner buy-in for consistent long-term PPID treatment. (dechra-us.com)